First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
Rigel Pharmaceuticals announced the first patient enrolled in a Phase 1b/2 triplet therapy trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, conducted by MD Anderson. The trial aims to determine safety, tolerability, and complete remission rates in newly diagnosed and relapsed/refractory patients.
Related Clinical Trials
Reference News
Rigel Pharmaceuticals enrolls first subject in Phase Ib/II trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, aiming to determine safety and complete remission rate. This trial marks the first under a multi-year strategic alliance with MD Anderson, exploring olutasidenib's potential in various hematologic neoplasms.
Rigel Pharmaceuticals announced the first patient enrolled in a Phase 1b/2 triplet therapy trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, conducted by MD Anderson. The trial aims to determine safety, tolerability, and complete remission rates in newly diagnosed and relapsed/refractory patients.
Rigel Pharmaceuticals enrolls first subject in Phase Ib/II trial of REZLIDHIA (olutasidenib) combined with decitabine and venetoclax for mIDH1 AML, sponsored by MD Anderson. The trial aims to establish safety and recommended Phase II dose, followed by assessing complete remission rate in 60 patients. Rigel and MD Anderson's strategic alliance will explore olutasidenib's potential in various haematologic neoplasms and single-agent use in lower-risk MDS and CCUS.